Amifostine Review

What amifostine is actually used for

Amifostine is indicated as an adjunct to specific cancer treatments: to help prevent or lessen some side effects of cisplatin (notably renal toxicity) and to reduce radiation-induced damage to salivary glands that causes dry mouth. Multiple clinical sources in the brief (Drugs.com, Cleveland Clinic, Mayo Clinic) state these two primary indications.

It is described across the sources as a supportive therapy rather than a primary anticancer drug — used only in the context of cisplatin chemotherapy or head/neck radiation regimens where protecting kidneys or salivary function is a clinical goal.

How and where amifostine is given

Amifostine is administered intravenously and must be given only by, or under the immediate supervision of, a physician. Sources consistently note the infusion takes place in a hospital or clinic setting rather than at home.

Because of the route and need for supervision, practical use requires facility access and staff trained to monitor for acute reactions and cardiovascular effects during and after infusion.

Key safety considerations and contraindications

Major cautions listed across the sources include dehydration, existing heart disease, history of stroke or transient ischaemic attack, irregular heartbeat, low blood pressure and low blood calcium; patients taking antihypertensive medications should inform their care team. Allergic reactions to amifostine or other agents are also noted as relevant precautions.

Elderly patients may not show geriatric-specific problems in studies cited, but clinicians are advised to use caution and consider dose adjustment if patients have age-related kidney, liver or heart disease. Pediatric use is not recommended; safety and efficacy in children have not been established. There are no adequate studies determining infant risk during breastfeeding.

Common monitoring needs and adverse-effect profile

Clinical summaries emphasize monitoring for cardiovascular effects (notably low blood pressure and related symptoms) and for allergic reactions; the Cleveland Clinic specifically lists low blood pressure and cardiovascular history as items patients must report before receiving amifostine.

Because of these risks, administration requires facility-based monitoring and pre-treatment assessment (hydration status, cardiac/neurologic history, current blood pressure and electrolytes such as calcium). The product is positioned as requiring active clinical oversight rather than unsupervised outpatient use.

Practical and population limitations

Amifostine is only described for adult use in the reviewed sources; pediatric administration is not recommended and safety/efficacy are unestablished in children. Breastfeeding safety data are inadequate according to Mayo Clinic summaries.

Because it must be infused under physician supervision and monitored for blood-pressure and cardiac issues, logistical barriers include clinic access and the need to manage existing cardiovascular or hydration problems before administration.

Pros & Cons

• ✅ Specifically indicated to reduce cisplatin-related kidney injury (stated across Drugs.com, Cleveland Clinic, Mayo Clinic)
• ✅ Used to decrease radiation-induced salivary gland damage and resultant dry mouth in head/neck radiation (Cleveland Clinic, Drugs.com)
• ✅ Intravenous administration under supervision allows immediate clinical management of acute reactions (Drugs.com, Cleveland Clinic)
• ✅ Major clinical resources (Cleveland Clinic, Mayo Clinic, Drugs.com) include amifostine in supportive-care guidance for adults
• ✅ Geriatric notes: studies cited have not demonstrated geriatric-specific problems, though caution is advised if comorbid organ disease is present (Mayo Clinic)

• ❌ Requires clinic- or hospital-based IV infusion with immediate physician supervision — not suitable for at-home use (Drugs.com, Cleveland Clinic)
• ❌ Important cardiovascular cautions: patients with heart disease, history of stroke/TIA, irregular heartbeat or low blood pressure need evaluation before use (Cleveland Clinic)
• ❌ Not recommended for pediatric use; safety and efficacy in children are not established (Drugs.com, Mayo Clinic)
• ❌ Breastfeeding safety is unknown — no adequate studies to determine infant risk (Mayo Clinic)
• ❌ Requires pre-treatment assessment for hydration and electrolytes; practical logistics can limit access

How It Compares to the Competition

• Palifermin (Kepivance) — A different cytoprotective biologic used in oncology supportive care; not evaluated in the sources reviewed for this brief.
• Dexrazoxane (Zinecard) — An alternative cardioprotective agent used with specific chemotherapies; not discussed in the provided source material for amifostine.
• Supportive care measures (aggressive IV hydration & treatment planning) — Non-drug or protocol-based alternatives commonly used to manage cisplatin renal risk and radiation effects; these approaches were not detailed in the reviewed sources.

Who Should Buy This & Who Should Skip It

Buy it if: Adults receiving cisplatin chemotherapy or radiation to the head and neck who need targeted protection of kidneys or salivary glands and who can receive IV therapy in a monitored clinic or hospital setting.

Skip it if: Parents seeking protection options for pediatric patients (amifostine is not recommended for children), patients without reliable clinic access for supervised IV infusion, and breastfeeding mothers where infant risk cannot be determined from available data.